<DOC>
	<DOCNO>NCT00671372</DOCNO>
	<brief_summary>This study ass safety pharmacokinetics add dulanermin Camptosar®/Erbitux® FOLFIRI regimen ( Camptosar® , 5-FU , leucovorin ) plus bevacizumab ( Cohort 6 subject receive prior bevacizumab therapy ) .</brief_summary>
	<brief_title>A Study Dulanermin Administered Combination With Camptosar®/Erbitux® Chemotherapy FOLFIRI ( With Without Bevacizumab ) Subjects With Previously Treated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed Informed Consent Form Age &gt; = 18 year Histologically confirm CRC evidence metastasis measurable tumor lesion ( ) Progression disease follow , intolerance , treatment 5fluorouracilbased therapy Progression disease within = &lt; 6 month follow last dose prior firstline treatment fluoropyrimidine oxaliplatinbased chemotherapy plus bevacizumab metastatic disease Use effective mean contraception woman childbearing potential men partner childbearing potential ( use per institutional standard ) Life expectancy &gt; 3 month Willingness capability accessible study followup Prior radiotherapy measurable , metastatic lesion ( ) use measure response Radiation therapy peripheral lesion within 14 day prior Day 1 ; Radiation therapy thoracic , abdominal pelvic field within 28 day prior Day 1 Chemotherapy , hormonal therapy , immunology within 4 week prior Day 1 Previous exposure DR4targeted therapy DR5targeted therapy Evidence clinically detectable ascites Day Other invasive malignancy within 5 year prior Day 1 ( basal cell carcinoma skin situ carcinoma cervix ) History evidence upon physical examination CNS disease Active infection require parenteral antibiotic Day 1 Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 anticipation need major surgical procedure course study fine needle aspiration within 7 day prior Day 1 Pregnancy lactation Serious nonhealing wound , ulcer , bone fracture Current recent participation another experimental drug study Clinically significant cardiovascular disease History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Cohort 5 : Subjects Kras mutation exclude enrollment The following exclusion criterion apply subject receive prior bevacizumab enrol Cohort 6 : four prior dos bevacizumab therapy , inadequately control hypertension , history hypertensive crisis hypertensive encephalopathy , history arterial thromboembolic event 6 month prior Day 1 , proteinuria , history abdominal fistula gastrointestinal perforation within 6 month prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>CRC</keyword>
	<keyword>Metastatic CRC</keyword>
	<keyword>APO2L/TRAIL</keyword>
</DOC>